ReviewInfectious diseases and therapy2014
Hypoxia-Inducible Factor (HIF) as a Pharmacological Target for Prevention and Treatment of Infectious Diseases.
Review in Infectious diseases and therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 52 citations in OpenAlex.
- Roxadustat and incidence of peritoneal dialysis-associated peritonitis: a propensity score-matched cohort study.Clinical and experimental nephrology · 2026Article
- HIF-1α at the intersection of hypoxia, ferroptosis-associated stress, and cell death crosstalk in osteomyelitis.Frontiers in cell and developmental biology · 2026Review
- Article
- Hypoxia-Inducible Factor 1-Alpha (HIF-1α): An Essential Regulator in Cellular Metabolic Control.Cureus · 2024Review
- Targeting hypoxia-inducible factors: therapeutic opportunities and challenges.Nature reviews. Drug discovery · 2024Review
- Unraveling the role of HIF and epigenetic regulation in pulmonary arterial hypertension: implications for clinical research and its therapeutic approach.Frontiers in medicine · 2024Review
- Immunomodulatory activity of manganese dioxide nanoparticles: Promising for novel vaccines and immunotherapeutics.Frontiers in immunology · 2023Review
- Loss ofFrontiers in cellular and infection microbiology · 2022Article
- Mechanisms controlling bacterial infection in myeloid cells under hypoxic conditions.Cellular and molecular life sciences : CMLS · 2021Review
- Analysis of Salivary Microbiome and Its Association With Periodontitis in Patients With Obstructive Sleep Apnea.Frontiers in cellular and infection microbiology · 2021Article
- Stabilization of Hypoxia-Inducible Factor Promotes Antimicrobial Activity of Human Macrophages AgainstFrontiers in immunology · 2021Article
- Transcription Factors Interplay Orchestrates the Immune-Metabolic Response ofFrontiers in cellular and infection microbiology · 2021Review
- Review
- Antimicrobial Resistance in ESKAPE Pathogens.Clinical microbiology reviews · 2020Review
- A comparative transcriptome approach for identification of molecular changes in Aphanomyces invadans infected Channa striatus.Molecular biology reports · 2018Article
- Hypoxia-inducible factor-1α regulation of myeloid cells.Journal of molecular medicine (Berlin, Germany) · 2018Review
- Low dose radiation primed iNOS + M1macrophages modulate angiogenic programming of tumor derived endothelium.Molecular carcinogenesis · 2018Article
- Hypoxia, Metabolism and Immune Cell Function.Biomedicines · 2018Review
- Review
- HIF-1alpha and infectious diseases: a new frontier for the development of new therapies.Revista do Instituto de Medicina Tropical de Sao Paulo · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
In the present era of ever-increasing antibiotic resistance and increasingly complex and immunosuppressed patient populations, physicians and scientists are seeking novel approaches to battle difficult infectious disease conditions. Development of a serious infection implies a failure of innate immune capabilities in the patient, and one may consider whether pharmacological strategies exist to correct and enhance innate immune cell function. Hypoxia-inducible factor-1 (HIF-1), the central regulator of the cellular response to hypoxic stress, has recently been recognized to control the activation state and key microbicidal functions of immune cells. HIF-1 boosting drugs are in clinical development for anemia and other indications, and could be repositioned as infectious disease therapeutics. With equal attention to opportunities and complexities, we review our current understanding of HIF-1 regulation of microbial host-pathogen interactions with an eye toward future drug development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.